Smith TJ, Khatcheressian J, Lyman GH, et al. 2006. 2006 update of recommendations for the use of white blood cell growth fac- tors: an evidence-based clinical practice guideline. J Clin Oncol, 24:3187–205. Soiffer R, Hodi FS, Haluska F, et al. 2003. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte- macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol, 21:3343–50. Soiffer R, Lynch T, Mihm M, et al. 1998. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte- macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci, USA, 95:13141–6. Stanley E, Lieschke GJ, Grail D, et al. 1994. Granulocyte/macrophage colony-stimulating factor-deﬁcient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci, USA, 91:5592–6. Tate J, Olencki T, Finke J, et al. 2001. Phase I trial of simultaneously admin- istered GM-CSF and IL-6 in patients with renal-cell carcinoma: clinical and laboratory effects. Ann Oncol, 12:655–9. Urbini B, Arpinati M, Bonifazi F, et al. 2003. Allogeneic graft CD34(+) cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant. Exp Hematol, 31:959–65. Vaughan MM, Moore J, Riches PG, et al. 2000. GM-CSF with biochemo- therapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanoma. Ann Oncol, 11:1183–9. Venugopal P, Sivaraman S, Huang XK, et al. 2000. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. Leuk Res, 24:411–5. Vereecque R, Buffenoir G, Preudhomme C, et al. 2000. Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Therapy, 7:1312–16. Verra N, De Jong D, Bex A, et al. 2005. Inﬁltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. Eur Urol, 48:527–33. Verra N, Jansen R, Groenewegen G, et al. 2003. Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma. Br J Cancer, 88:1346–51. Clinical uses of GM-CSF Volpi I, Perruccio K, Tosti A, et al. 2001. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recov- ery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood, 97:2514–21. Waller EK, Rosenthal H, Jones TW, et al. 2001. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood, 97:2948–56. Wang HY, Wang RF. 2007. Regulatory T cells and cancer. Current Opinion in Immunology, 19:217–23. Weber RW, O’Day S, Rose M, et al. 2005. Low-dose outpatient che- mobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-{alpha}2b, and recombinant inter- leukin-2 for the treatment of metastatic melanoma. J Clin Oncol, 23:8992–9000. Westermann J, Reich G, Kopp J, et al. 2001. Granulocyte/macrophage- colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma:a pilot study. Cancer Immunol Immunother, 49:613–20. Whiteway A, Corbett T, Anderson R, et al. 2003. Expression of co- stimulatory molecules on acute myeloid leukaemia blasts may effect duration of ﬁrst remission. Br J Haematol, 120:442–51. Wos E, Olencki T, Tuason L, et al. 1996. Phase II trial of subcutane- ously administered granulocyte-macrophage colony-stimulating factor in patients with metastatic renal cell carcinoma. Cancer, 77:1149–53. Yagci M, Akar I, Sucak GT, et al. 2005. GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes. Leuk Res, 29:735–8. Zhan Y, Lieschke GJ, Grail D, et al. 1998. Essential roles for granulocyte- macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenes-infected mice. Blood, 91:863–9. Zittoun R , Suciu S , Mandelli F, et al. 1996. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia:a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol, 14:2150–9. Biologics:Targets & Therapy 2008:2(1) 27